Common diabetes drug linked to heart disease: This is what the study says

For many living with type 2 diabetes, managing blood sugar is a daily reality. Often, medications come as a lifeline, and among them, sulfonylureas like glipizide are popular choices, especially in the US. They’ve been around for decades, are affordable, and have shown effective results in keeping glucose in check. But now, a new study has cast a shadow over this commonly used medicine. Researchers have discovered a possible link between glipizide and increased heart-related risks.


Here’s what the study found, what it truly means, and why this matters.

Glipizide belongs to a group of drugs called sulfonylureas. For decades, these medications have been trusted for lowering blood sugar in people with type 2 diabetes.


But popularity doesn’t always mean perfection. The latest study , "Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors," published in JAMA Network, signals a possible red flag, which should not be ignored. Involving nearly 48,000 individuals, this research found that those taking glipizide had a higher risk of heart attacks, strokes, heart failure hospitalisations, and even cardiovascular-related deaths than those taking a newer class of drugs called DPP-4 inhibitors.

Not just about the numbers, but about what they mean

It’s easy to be alarmed by statistics. But what do these numbers truly tell us? Let's see..

Firstly, the study doesn't claim that glipizide causes heart problems directly. What it suggests is a possible association, a pattern that raises concerns, especially in people already facing moderate cardiovascular risk.


The heart, after all, is already under pressure in type 2 diabetes. When a drug meant to help with sugar control potentially adds to that risk, even slightly, it becomes a serious discussion for healthcare providers.

The research hints that for people with type 2 diabetes who have some risk of heart disease, using glipizide (and possibly other sulfonylureas) might not be the best treatment option, and other medications could be safer or more effective for them.

What this means for families dealing with diabetes

This isn’t about pushing panic buttons. Glipizide is still an approved and effective drug. But the study offers important insights for personalised diabetes management. It’s a reminder that medications work differently for different people, and what works well for one might not be ideal for another, especially when silent risks like cardiovascular strain are involved.

(Inputs from IANS)

[Disclaimer: This article is intended for informational purposes only. It does not substitute professional medical advice, diagnosis, or treatment. Individuals should consult their healthcare provider before making any changes to their medication or treatment plan.]